PE20250781A1 - Composicion farmaceutica y que comprende derivados de difenildiazol metodos de uso - Google Patents
Composicion farmaceutica y que comprende derivados de difenildiazol metodos de usoInfo
- Publication number
- PE20250781A1 PE20250781A1 PE2024001775A PE2024001775A PE20250781A1 PE 20250781 A1 PE20250781 A1 PE 20250781A1 PE 2024001775 A PE2024001775 A PE 2024001775A PE 2024001775 A PE2024001775 A PE 2024001775A PE 20250781 A1 PE20250781 A1 PE 20250781A1
- Authority
- PE
- Peru
- Prior art keywords
- diphenyldiazole
- pharmaceutical composition
- fatty acid
- polyethylene glycol
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan composiciones farmaceuticas que comprenden un compuesto de difenildiazol de la formula general (A) o (A ) y metodos para usarlas para el tratamiento de enfermedades neurodegenerativas, en particular alfa-sinucleinopatias. Se refiere a una composicion farmaceutica, que comprende por lo menos un compuesto que tiene la formula general (A) o (A ) o un estereoisomero, racemato, hidrato o solvato de este, en donde R es H, alquilo C1-4 y -alquileno C1-4-halogeno; Hal es F, Cl, Br e I; y RE7 y RE8 son independientemente H o F; y un excipiente farmaceuticamente aceptable, que es por lo menos un monoester de un acido graso y polietilenglicol y/o un diester de un acido graso y polietilenglicol, en donde el acido graso es acidos grasos C8-C22; y el polietilenglicol es polietilenglicoles que contienen aproximadamente 20 hasta aproximadamente 40 unidades de oxido de etileno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22159408 | 2022-03-01 | ||
| PCT/EP2023/055160 WO2023166045A1 (en) | 2022-03-01 | 2023-03-01 | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20250781A1 true PE20250781A1 (es) | 2025-03-14 |
Family
ID=80623476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001775A PE20250781A1 (es) | 2022-03-01 | 2023-03-01 | Composicion farmaceutica y que comprende derivados de difenildiazol metodos de uso |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250161273A1 (es) |
| EP (1) | EP4486340A1 (es) |
| JP (1) | JP2025508912A (es) |
| KR (1) | KR20240155237A (es) |
| CN (1) | CN118715010A (es) |
| AU (1) | AU2023227368A1 (es) |
| CA (1) | CA3246018A1 (es) |
| CL (1) | CL2024002379A1 (es) |
| IL (1) | IL314952A (es) |
| MX (1) | MX2024009773A (es) |
| PE (1) | PE20250781A1 (es) |
| WO (1) | WO2023166045A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025068949A1 (en) | 2023-09-26 | 2025-04-03 | Teva Pharmaceutical Industries Ltd. | Emrusolmin for use in treating multiple system atrophy |
| KR20250090047A (ko) * | 2023-12-12 | 2025-06-19 | 가천대학교 산학협력단 | 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2862923T3 (es) * | 2008-06-09 | 2021-10-08 | Univ Muenchen Ludwig Maximilians | Nuevos fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas |
| PT3390412T (pt) * | 2015-12-14 | 2021-06-22 | Max Planck Gesellschaft Zur Foerderung Der Wss | Derivados solúveis em água de compostos de 3,5-difenil-diazole |
-
2023
- 2023-03-01 AU AU2023227368A patent/AU2023227368A1/en active Pending
- 2023-03-01 US US18/840,374 patent/US20250161273A1/en active Pending
- 2023-03-01 KR KR1020247029979A patent/KR20240155237A/ko active Pending
- 2023-03-01 CN CN202380024479.XA patent/CN118715010A/zh active Pending
- 2023-03-01 EP EP23707119.6A patent/EP4486340A1/en active Pending
- 2023-03-01 PE PE2024001775A patent/PE20250781A1/es unknown
- 2023-03-01 MX MX2024009773A patent/MX2024009773A/es unknown
- 2023-03-01 WO PCT/EP2023/055160 patent/WO2023166045A1/en not_active Ceased
- 2023-03-01 CA CA3246018A patent/CA3246018A1/en active Pending
- 2023-03-01 JP JP2024550866A patent/JP2025508912A/ja active Pending
- 2023-03-01 IL IL314952A patent/IL314952A/en unknown
-
2024
- 2024-08-08 CL CL2024002379A patent/CL2024002379A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024009773A (es) | 2024-08-19 |
| EP4486340A1 (en) | 2025-01-08 |
| CA3246018A1 (en) | 2023-09-07 |
| CL2024002379A1 (es) | 2025-01-24 |
| JP2025508912A (ja) | 2025-04-10 |
| AU2023227368A1 (en) | 2024-07-18 |
| KR20240155237A (ko) | 2024-10-28 |
| WO2023166045A1 (en) | 2023-09-07 |
| IL314952A (en) | 2024-10-01 |
| US20250161273A1 (en) | 2025-05-22 |
| CN118715010A (zh) | 2024-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20250781A1 (es) | Composicion farmaceutica y que comprende derivados de difenildiazol metodos de uso | |
| PE20231081A1 (es) | Derivados de quinoxalina como farmacos contra el cancer | |
| RU2483061C2 (ru) | Тетрагидропиранохроменовые ингибиторы гамма-секретазы | |
| EP2581376A4 (en) | MATRINIC ACID / MATRINE DERIVATIVES AND METHODS OF PREPARATION AND USES THEREOF | |
| PE20232051A1 (es) | Compuestos carboxi-benzimidazol moduladores de glp-1r | |
| AR118768A1 (es) | Derivados de pirimidina como inhibidores de las cinasas jak | |
| AR070299A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas, usos y composiciones farmaceuticas | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
| JP2013525286A5 (es) | ||
| AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
| AR073117A1 (es) | Derivado de aminometil-fenil-piperidin-1-il-indolil-metanona, inhibidores de la triptasa de mastocitos, composiciones farmaceuticas que lo contienen, metodo de preparacion, compuestos intermediarios y uso del compuesto en el tratamiento de procesos inflamatorios. | |
| RU2015120376A (ru) | Новые антибактериальные соединения и их биологическое применение | |
| PE20241474A1 (es) | Compuestos que contienen heteroatomos y usos de estos | |
| AR022220A1 (es) | Derivados de la imidazo[4,5-c]-piridin-4-ona, un procedimiento para su preparacion, el empleo de los mismos para preparar un medicamento, los medicamentosa base de estos compuestos, las composiciones farmaceuticas que contienen estos compuestos y un procedimiento para preparar estas composiciones fa | |
| AR133240A1 (es) | Compuestos, composiciones y métodos | |
| PE20251401A1 (es) | Inhibidores de topoisomerasa-1 derivados de exatecan composiciones farmaceuticas y sus usos | |
| AR127431A1 (es) | Compuestos novedosos | |
| AR065419A1 (es) | Metodo para inhibir la proliferacion de celulas tumorales | |
| AR039027A1 (es) | Compuesto de los acidos 4-[(8-substituido)-6-cromanoil] y 4-[(8-substituido)-croman-6-il-etinil]-benzoico y fenilacetico, composicion farmaceutica que lo comprende y su uso para prepararla | |
| PE20241186A1 (es) | Compuestos de cd73 | |
| AR128917A1 (es) | Inhibidores de malt-1 de tiazolo[5,4-b]piridina | |
| CO2021006087A2 (es) | Compuestos aromáticos y usos farmacéuticos de los mismos | |
| RU2017137960A (ru) | Применение тиаоксосоединений для уменьшения содержания аро сз | |
| AR125312A1 (es) | Derivados heterocíclicos, composiciones farmacéuticas y su uso en el tratamiento o la mejora del cáncer |